PWMG
NBIX icon

Prestige Wealth Management Group’s Neurocrine Biosciences NBIX Stock Holding History

Prestige Wealth Management Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$675 Hold
4
– – ﹤0.01% 983
2026
Q1 		$527 Hold
4
– – ﹤0.01% 957
2025
Q4 		$568 Hold
4
– – ﹤0.01% 932
2025
Q3 		$562 Sell
4
-21
-84% -$2.85K ﹤0.01% 921
2025
Q2 		$3.14K Sell
25
-19
-43% -$2.18K ﹤0.01% 651
2025
Q1 		$4.87K Hold
44
– – ﹤0.01% 566
2024
Q4 		$6.01K Buy
44
+19
+76% +$2.35K ﹤0.01% 560
2024
Q3 		$2.88K Buy
25
+2
+9% +$274 ﹤0.01% 703
2024
Q2 		$3.17K Buy
23
+3
+15% +$411 ﹤0.01% 633
2024
Q1 		$2.76K Sell
20
-18
-47% -$2.46K ﹤0.01% 691
2023
Q4 		$5.01K Buy
38
+21
+124% +$2.42K ﹤0.01% 584
2023
Q3 		$1.91K Buy
17
+13
+325% +$1.37K ﹤0.01% 747
2023
Q2 		$378 Sell
4
-18
-82% -$1.76K ﹤0.01% 1015
2023
Q1 		$2.23K Sell
22
-44
-67% -$4.58K ﹤0.01% 727
2022
Q4 		$7.88K Buy
66
+27
+69% +$3.16K ﹤0.01% 510
2022
Q3 		$4K Buy
39
+6
+18% +$609 ﹤0.01% 603
2022
Q2 		$3K Hold
33
– – ﹤0.01% 697
2022
Q1 		$3K Buy
+33
New +$2.8K ﹤0.01% 722
2021
Q2 		– Sell
-67
Closed -$6K – 1007
2021
Q1 		$6K Buy
67
+23
+52% +$2.41K ﹤0.01% 584
2020
Q4 		$4K Buy
+44
New +$4.25K ﹤0.01% 637

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Prestige Wealth Management Group's NBIX Position: Q2 2026 in Review

Prestige Wealth Management Group held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 4 shares worth $675. The position accounts for ﹤0.01% of the portfolio, ranked #983.

Prestige Wealth Management Group first reported a position in NBIX in Q4 2020 and has held it in 20 quarters since. The position peaked at $7.88K in Q4 2022. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Prestige Wealth Management Group held 4 shares of Neurocrine Biosciences worth $675 as of Q2 2026.
  • Prestige Wealth Management Group left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q2 2026, its #983 holding.
  • Prestige Wealth Management Group first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 20 quarters since.
  • Prestige Wealth Management Group's Neurocrine Biosciences position peaked at $7.88K in Q4 2022.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.